Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A and R1 to R4 are as described heroin, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Abstract: A method for operating a magnetic resonance device is provided. The magnetic resonance device includes a component that has an operating limit in relation to a state parameter. The component uses a protocol to record magnetic resonance data. The protocol includes a magnetic resonance sequence and is described by protocol parameters. A protocol parameter set that, in relation to a protocol section, allows the protocol section to be repeated as often as desired without exceeding the operating limit is provided or determined. The method includes receiving a boost parameter from a user interface. At least for the protocol section, adaptation parameters are determined at least partially automatically based on the boost parameter, such that the desired number of repetitions described by the boost parameter is established while complying with the operating limit. Magnetic resonance data is recorded with the protocol using the determined adaptation parameters.

Abstract: The invention provides new MAGL inhibitors having the general formula (II)AB(II) wherein the variables are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Abstract: The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.

Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.

Abstract: The invention provides new MAGL inhibitors having the general formula (I) wherein the variables are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Abstract: The present invention provides new bicyclic tetrahydroazepine derivatives having the general formula (I), wherein X, Y, R1, R2, R3, R4, R5, R6, R6a are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using them in the treatment of cancer.

Abstract: The invention provides new reversible monoacylglycerol lipase (MAGL) inhibitors that are useful for the treatment or prophylaxis of diseases or conditions associated with MAGL. The reversible MAGL inhibitors according to the present invention may also be labeled with radioisotopes and are thus useful for medical imaging, such as positron-emission tomography (PET) and/or autoradiography.

Abstract: The invention relates to novel compounds having the general formula I wherein R1, R2, R3, R4, R5, R6, R7, W, m and n are as described herein, composition including the compounds and methods of using the compounds.

Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, X, and R1 to R7 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein B, C, L, X, Y, RL and R3 to R5 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Abstract: The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.

Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L1, X, m, n, and R1 to R7 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Abstract: The present disclosure relates to an applicator device for depositing a lubricant onto an inside surface of a barrel of a medicament container. The applicator device includes a sprayer defining a longitudinal direction and sized for insertion into an interior of the barrel along the longitudinal direction. The sprayer is operable to eject the lubricant. A centering element is connected to the sprayer and operably engageable with the barrel in a predefined position or orientation to align the sprayer relative to the barrel.

Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M and C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.

Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein X, Y, Z, A, L, B, and R1 to R3 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1, R2 and R3 are as described herein, pharmaceutically acceptable salts thereof, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.